Works matching IS 03407004 AND DT 2022 AND VI 71 AND IP 7
Results: 20
Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15–16, 2020.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1787, doi. 10.1007/s00262-022-03145-0
- By:
- Publication type:
- Article
Chemical screening identifies novel small molecule activators of natural killer cell cytotoxicity against cancer cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1671, doi. 10.1007/s00262-021-03117-w
- By:
- Publication type:
- Article
Metformin inhibits human non-small cell lung cancer by regulating AMPK–CEBPB–PDL1 signaling pathway.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1733, doi. 10.1007/s00262-021-03116-x
- By:
- Publication type:
- Article
The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1693, doi. 10.1007/s00262-021-03115-y
- By:
- Publication type:
- Article
Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1719, doi. 10.1007/s00262-021-03114-z
- By:
- Publication type:
- Article
Identification of prognostic genes in the pancreatic adenocarcinoma immune microenvironment by integrated bioinformatics analysis.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1757, doi. 10.1007/s00262-021-03110-3
- By:
- Publication type:
- Article
Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1705, doi. 10.1007/s00262-021-03109-w
- By:
- Publication type:
- Article
Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1747, doi. 10.1007/s00262-021-03108-x
- By:
- Publication type:
- Article
Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1681, doi. 10.1007/s00262-021-03106-z
- By:
- Publication type:
- Article
Distribution, phenotype, functional and clinical relevance of CD8<sup>+</sup>CD103<sup>+</sup> tissue-resident memory T cells in human gastric cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1645, doi. 10.1007/s00262-021-03105-0
- By:
- Publication type:
- Article
Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11–13 2019, Verona, Italy.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1777, doi. 10.1007/s00262-021-03104-1
- By:
- Publication type:
- Article
Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1633, doi. 10.1007/s00262-021-03103-2
- By:
- Publication type:
- Article
Efficient adoptive transfer of autologous modified B cells: a new humanized platform mouse model for testing B cells reprogramming therapies.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1771, doi. 10.1007/s00262-021-03101-4
- By:
- Publication type:
- Article
Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1625, doi. 10.1007/s00262-021-03100-5
- By:
- Publication type:
- Article
Redirecting host preexisting influenza A virus immunity for cancer immunotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1611, doi. 10.1007/s00262-021-03099-9
- By:
- Publication type:
- Article
Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1549, doi. 10.1007/s00262-021-03097-x
- By:
- Publication type:
- Article
Identification of HLA-A2 restricted epitopes of glypican-3 and induction of CTL responses in HLA-A2 transgenic mice.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1569, doi. 10.1007/s00262-021-03096-y
- By:
- Publication type:
- Article
Robust immune response stimulated by in situ injection of CpG/αOX40/cGAMP in αPD-1-resistant malignancy.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1597, doi. 10.1007/s00262-021-03095-z
- By:
- Publication type:
- Article
TGF-β orchestrates the phenotype and function of monocytic myeloid-derived suppressor cells in colorectal cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1583, doi. 10.1007/s00262-021-03081-5
- By:
- Publication type:
- Article
Endoplasmic reticulum stress-induced release and binding of calreticulin from human ovarian cancer cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 7, p. 1655, doi. 10.1007/s00262-021-03072-6
- By:
- Publication type:
- Article